Natera to Report its Third Quarter Results on November 5, 2026

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2026, after the market closes on November 5, 2026. Natera will host a conference call and webcast shortly thereafter at 4:30 p.m. ET. Earnings Conference Call Information   Event: Natera's Third Quarter 2026 Financial Results Date: November 5, 2026 Time: 4:30 p.m. ET Live Dial-In: 1-833-461-57.

Business Wire • 12 hours ago

Natera (NTRA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • 9 hours ago

Alger Dynamic Opportunities Fund Q3 2026 Portfolio Update

Class A shares of the Alger Dynamic Opportunities Fund underperformed the S&P 500 Index during the third quarter of 2026. During the quarter, long positions, in aggregate, detracted from both absolute and relative performance. Short positions, in aggregate, contributed to both absolute and relative performance.

Seeking Alpha • 19 hours ago

Parnassus Mid Cap Growth Fund: Q3 2026 Performance Review

The portfolio's outperformance was primarily driven by our holdings in the Health Care sector, which delivered strong returns for the quarter on company-specific catalysts. Information Technology holdings and underweight to the Energy sector detracted from returns. For the year-to-date period, the Fund returned 5.80% (net of fees), outperforming the Russell Midcap Growth Index's 1.01%.

Seeking Alpha • 9 hours ago

NTRA Q3 Earnings on Deck: Will Signatera Volume Growth Drive Results?

Natera's third-quarter 2026 results hinge on Signatera volume growth, regulatory milestones and higher test prices, while expanding Medicare coverage may boost organ health revenues.

Zacks Investment Research • Oct 28, 2026

Weatherbie Specialized Growth Fund Q3 2026 Portfolio Update

Natera reported stronger-than-expected results and raised its full-year outlook. Impinj reported stronger-than-expected results, including record revenue and profitability. Hamilton Lane shares contributed positively during the quarter after the company reported stronger-than-expected revenue and earnings.

Seeking Alpha • Oct 28, 2026

Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided a summary of key findings from the European Society for Medical Oncology (ESMO) Congress 2026. Following the presentation of several late-breaking datasets over the weekend, Natera's technology was included in 25 abstracts, including 9 oral presentations, along with two concurrent publications. Results from the phase III VOLGA trial in muscle-invasive bladder canc.

Business Wire • Oct 27, 2026

Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the American Society of Nephrology (ASN) Kidney Week 2026, highlighting the unique value genetic testing can provide for patients with CKD. These 18 abstracts, including three oral presentations, add to the growing support for Renasight, Natera's genetic test for CKD. Among the key findings were data from a large, real-worl.

Business Wire • Oct 26, 2026

Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree.

Druckenmiller owns a large stake in Natera. The company is growing quickly by disrupting the healthcare testing market.

The Motley Fool • Oct 26, 2026

Natera Partners With TransCode to Advance Colorectal Cancer Trial

NTRA partners with TransCode Therapeutics to use Signatera MRD testing in a Phase 2a colorectal cancer trial, aiming to accelerate enrollment and research.

Zacks Investment Research • Oct 21, 2026